Apotex

Coherus Biosciences Inc (NASDAQ: CHRS) shares were down steeply in pre-market trading after the company announced it has received a complete response letter from the FDA for its abiologic license application, or aBLA, for CHS-1701, a pegfilgrastim biosimilar candidate to Amgen, Inc. (...